Vizient to Present at FDA Hearing on the Future of Insulin Biosimilars
IRVING, Texas--(BUSINESS WIRE)--May 13, 2019--Vizient Inc. announces that Steven Lucio, PharmD, BCPS, vice president, pharmacy solutions, will present on behalf of the company and its member hospitals at the Food and Drug Administration’s (FDA) public hearing “ The Future of Insulin Biosimilars: Increasing Access and Facilitating the Efficient Development of Biosimilar and Interchangeable Insulin Products,” being held from 9 a.m. to 2:45 p.m. today at the FDA White Oak Campus in Silver Spring, Maryland. The hearing will give industry experts the opportunity to offer insights to the FDA on how to facilitate the development of insulin biosimilars and other interchangeable insulin products to address the soaring cost for these life-saving medications for diabetic patients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190513005120/en/
Steven Lucio, PharmD, BCPS, Vizient vice president of pharmacy solutions, presents at the Food and Drug Administration’s public hearing “The Future of Insulin Biosimilars: Increasing Access and Facilitating the Efficient Development of Biosimilar and Interchangeable Insulin Products” May 13, 2019. (Photo: Business Wire)
“Vizient fully endorses the scientific principles of biosimilarity, and we believe that molecules necessary to create insulin are well suited for the creation of a biosimilar option for providers and patients,” said Lucio. “Insulin biosimilars, once approved, will bring much needed, new competition to the market and will offer more affordable treatment options to patients with diabetes.”
Since 2010, Vizient has provided ongoing training and education on the biosimilar paradigm to its provider members in the form of over 200 in-person presentations and web conferences. We have also developed evidence-based clinical resources to support members in their formulary evaluations of approved and pending biosimilars, and we’ve worked with existing and future biosimilar manufacturers on contractual relationships to maximize the value and cost savings opportunities for our membership. At present, Vizient has over 50 pharmacists and other subject matter expert resources working to facilitate the appropriate use of biosimilars and document the financial value and sustained high quality care associated with these agents.
Vizient is the nation’s largest health care performance improvement company serving a diverse membership that includes academic medical centers, pediatric facilities, community hospitals, integrated health care delivery networks and non-acute health care providers.
The hearing is open to the public. To watch the hearing on a live stream webcast, go to: https://collaboration.fda.gov/insulin051319.
About Vizient, Inc.
Vizient, Inc., the largest member-driven health care performance improvement company in the country, provides innovative data-driven solutions, expertise and collaborative opportunities that lead to improved patient outcomes and lower costs. Vizient’s diverse membership base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers and represents approximately $100 billion in annual purchasing volume. In 2019, Vizient again received a World’s Most Ethical Company designation from the Ethisphere Institute. Vizient’s headquarters are in Irving, Texas, with locations in Chicago and other cities across the United States. Please visit www.vizientinc.com as well as our newsroom, blog, Twitter, LinkedIn and YouTube pages for more information about the company.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190513005120/en/
CONTACT: Angie Boliver
KEYWORD: UNITED STATES NORTH AMERICA TEXAS
INDUSTRY KEYWORD: PRACTICE MANAGEMENT HEALTH BIOTECHNOLOGY HOSPITALS PHARMACEUTICAL FDA MEDICAL SUPPLIES
SOURCE: Vizient, Inc.
Copyright Business Wire 2019.
PUB: 05/13/2019 06:00 AM/DISC: 05/13/2019 06:01 AM